```html

Jerusalem Disease (Lepromatous Leprosy)

Overview

Jerusalem disease is an older term for the most severe form of leprosy, known today as lepromatous leprosy. It is a chronic infectious disease caused by the bacterium Mycobacterium leprae. Unlike the tuberculoid (paucibacillary) form, lepromatous leprosy is characterized by a high bacterial load, widespread skin lesions, and involvement of the peripheral nerves, mucous membranes, and internal organs.

• Who it affects: Anyone can become infected, but the disease is most common in men aged 20‑40 years and in people with weakened cell‑mediated immunity (e.g., HIV infection, malnutrition, or certain genetic factors).
• Global prevalence: According to the World Health Organization (WHO), there were about 202,000 new leprosy cases worldwide in 2022, with lepromatous leprosy accounting for roughly 10‑15 % of those cases.
• Geographic distribution: Endemic regions include parts of South‑Asia (India, Bangladesh, Nepal), sub‑Saharan Africa, Brazil, and some Pacific islands. Sporadic cases still occur in non‑endemic countries through immigration or travel.

Symptoms

Lepromatous leprosy develops slowly, often over several years. The following symptoms are typical, but not every patient will have all of them.

Skin Manifestations

• Diffuse skin lesions: Numerous, symmetric macules, papules, nodules, or plaques that may be hypopigmented or erythematous. Lesions are usually non‑painful and can become thickened or ulcerated.
• Facial changes (Leonine facies): Thickening of the skin of the forehead, nose, cheeks and eyebrows, giving a “lion‑like” appearance.
• Loss of eyebrows and eyelashes (madarosis): Due to infiltration of hair follicles.
• Patchy alopecia: Hair loss on the scalp and body.

Nerve Involvement

• Symmetric peripheral neuropathy: Numbness, tingling, or burning sensations in the hands and feet.
• Motor weakness: Particularly in intrinsic hand muscles, leading to claw‑hand deformities.
• Loss of protective sensation increases risk of injuries, burns, and secondary infections.

Mucosal and Systemic Features

• Nasopharyngeal involvement: Nasal congestion, epistaxis, and loss of the sense of smell.
• Eye disease: Lagophthalmos, corneal ulceration, and blindness if untreated.
• Testicular involvement: Atrophy, infertility, or hypo‑testosterone.
• General symptoms: Low‑grade fever, weight loss, and malaise in advanced disease.

Causes and Risk Factors

Cause: The disease is caused by the obligate intracellular bacterium Mycobacterium leprae. The organism cannot be cultured on artificial media, and it grows best at temperatures of 30‑33 °C, which explains its predilection for cooler body areas (skin, peripheral nerves, nasal mucosa).

Transmission

• Prolonged, close contact with untreated lepromatous patients is the principal route, likely via respiratory droplets or skin‑to‑skin contact.
• Armadillos are a known animal reservoir in the southern United States; occasional zoonotic transmission has been documented.

Risk Factors

• Living in or traveling to endemic regions.
• Genetic susceptibility (e.g., polymorphisms in the LRRK2, PARK2 genes).
• Immunosuppression (HIV, diabetes, chronic steroid use).
• Malnutrition and poverty, which impair cell‑mediated immunity.
• Close household contact with an untreated lepromatous patient.

Diagnosis

Because early signs can mimic other dermatologic or neurologic conditions, a high index of suspicion is essential.

Clinical Evaluation

• Detailed skin and nerve examination.
• Documentation of lesion type, distribution, and nerve thickening.

Laboratory & Microbiologic Tests

• Skin smear (slit‐skin smear): Ziehl‑Neelsen staining to detect acid‑fast bacilli; a high bacterial index (>2) supports lepromatous disease.
• Skin biopsy: Histopathology shows a granulomatous infiltrate rich in foamy macrophages (Virchow cells) packed with bacilli.
• Polymerase chain reaction (PCR): Detects bacterial DNA; increasingly used for confirmation when smear results are equivocal.

Additional Tests

• Peripheral nerve conduction studies (to quantify neuropathy).
• Baseline ophthalmologic exam (to detect early eye involvement).
• Serologic screening for HIV, hepatitis B/C, and diabetes to identify co‑morbidities that influence treatment.

Treatment Options

The WHO recommends multidrug therapy (MDT) for all forms of leprosy. Lepromatous leprosy requires a longer, more intensive regimen.

First‑Line Multidrug Therapy

Drug	Dosage	Duration
Rifampicin 600 mg	Monthly supervised dose	12 months (minimum)
Dapsone 100 mg	Daily self‑administered
Clofazimine 300 mg	Monthly supervised dose + 50 mg daily

Adherence is critical; directly observed therapy (DOT) programs improve success rates.

Adjunctive Therapies

• Prednisone: Short courses (4–12 weeks) for acute neuritis or severe inflammatory reactions (type 2 lepra reactions).
• Thalidomide: Highly effective for chronic erythema nodosum leprosum (ENL) but requires strict teratogenicity precautions.
• Physiotherapy & orthotics: To preserve limb function and prevent deformities.

Lifestyle & Supportive Measures

• Nutrition: Adequate protein, vitamins A, C, and D support immune recovery.
• Skin care: Moisturize lesions, avoid trauma, treat secondary infections promptly.
• Eye protection: Use lubricating eye drops and sunglasses; seek ophthalmology follow‑up.
• Psychosocial support: Counseling and community stigma‑reduction programs improve adherence.

Living with Jerusalem disease (Lepromatous leprosy)

While the disease can be chronic, modern therapy allows most patients to lead normal lives.

Daily Management Tips

• Medication adherence: Keep a pillbox, set daily alarms, and attend monthly clinic visits.
• Self‑inspection: Examine feet and hands each evening for injuries, ulcers, or new lesions.
• Foot care: Wear well‑fitted shoes, use soft socks, and keep nails trimmed to prevent ulcers.
• Skin protection: Apply sunscreen to hypopigmented patches, avoid extreme temperatures that can cause burns.
• Vaccinations: Stay up‑to‑date on influenza, pneumococcal, and COVID‑19 vaccines—immune compromise can increase risk.
• Emotional health: Join support groups (e.g., Leprosy Mission, local NGOs) to combat stigma.

Follow‑up Schedule

• Monthly during the first six months of MDT for drug dispensing and clinical review.
• Every 3 months thereafter until treatment completion, then annually for at least 2 years to monitor for relapse or late complications.

Prevention

• Early case detection and treatment: Prompt MDT reduces bacterial load and transmission risk.
• Contact prophylaxis: Single‑dose rifampicin (SDR) given to close contacts has shown a 57 % reduction in new cases (WHO, 2021).
• Public health education: Community awareness programs that destigmatize leprosy encourage affected individuals to seek care.
• Environmental measures: Improved housing, sanitation, and nutrition lower susceptibility.
• Animal reservoir control: In regions with armadillo‑linked transmission, avoid handling wild armadillos.

Complications

If left untreated or inadequately treated, lepromatous leprosy can lead to serious, often irreversible complications.

• Peripheral neuropathy: Permanent loss of sensation and muscle weakness, leading to foot ulcers, deformities, and disability.
• Leprosy reactions: Type 1 (reversal) and Type 2 (ENL) inflammatory episodes cause pain, fever, and nerve damage.
• Eye disease: Corneal ulceration, cataracts, or blindness.
• Nasopharyngeal damage: Chronic rhinitis, septal perforation, and secondary infections.
• Testicular atrophy & infertility.
• Stigma and psychosocial impact: Social isolation, depression, and loss of employment.

When to Seek Emergency Care

References

1. World Health Organization. Global Leprosy Report 2022. https://www.who.int/publications/i/item/9789240048638

2. Mayo Clinic. Lepromatous leprosy: Symptoms and causes. https://www.mayoclinic.org/diseases‑conditions/leprosy/symptoms‑causes/syc‑20374288

3. Centers for Disease Control and Prevention. Leprosy (Hansen Disease). https://www.cdc.gov/leprosy/

4. National Institute of Health, National Library of Medicine. Mycobacterium leprae infection. https://www.ncbi.nlm.nih.gov/books/NBK459455/

5. Cleveland Clinic. Leprosy treatment guidelines. https://my.clevelandclinic.org/health/diseases/14749-leprosy

6. WHO. Single‑dose rifampicin for leprosy post‑exposure prophylaxis. 2021. https://www.who.int/publications/i/item/WHO‑NMF‑N70-2021

```